罗格列酮对2型糖尿病患者血浆成纤维细胞生长因子-21及胰岛素敏感性的影响

目的探讨罗格列酮对2型糖尿病患者FGF-21及胰岛素敏感性的影响。方法 2型糖尿病患者40例(治疗组)口服罗格列酮,4 mg,1次/d,疗程12周。另取健康体检者35例作为对照组。观察对照组及治疗组治疗前后FBG、2hBG、HbA1C、FIns、2hIns、血脂、FGF-21等生化指标。比较治疗组治疗前后GIR。结果治疗组治疗前FBG、2hBG、HbA1C、FIns、TC、LDL-C、FGF-21水平明显高于对照组(P<0.01);治疗组治疗后FBG、2hBG、HbA1C、FIns、TG、TC、LDL-C、FGF-21水平较治疗前明显降低(P<0.01)。治疗组治疗后GIR为明显高于治疗前(P<0.01)。结论罗格列酮可明显降低2型糖尿病患者血浆FGF-21水平,提高胰岛素敏感性。

Effect of rosiglitazone on FGF-21 and insulin sensitivity in patients with type 2 diabetes mellitus

Objective To investigate the effect of rosiglitazone on FGF-21 and insulin sensitivity in patients with type 2 diabetes mellitus.Methods Forty patients with T2DM(treatment group) received oral rosiglitazone,4 mg,1 times/d,for 12 weeks.Another 35 healthy patients were assigned to control group.Before and after treatment,FBG,2hBG,HbA1C,FIns,2hIns, lipids,FGF-21 and other biochemical markers were observed.The GIR in the treatment group before and after treatment was observed.Results Before treatment,FBG,2hBG,HbA1C,FIns,TC,LDL-C,FGF-21 levels were significantly higher in the treatment group than in the control group(P<0.01). In the treatment group,FBG,2hBG,HbA1C,FIns,TG,TC,LDL-C,FGF-21 levels were significantly lower than before treatment(P<0.01).After treatment,the GIR was significantly higher than that before treatment(P<0.01).Conclusion Rosiglitazone can significantly reduce the plasma of patients with type 2 diabetes,FGF-21 levels,and improve insulin sensitivity.